Status: In progress | |
Treatment of non-metastatic hormone-sensitive prostate cancer at high risk of progression. |
|
Medicine details |
|
Medicine name | abiraterone acetate (Zytiga®) |
Formulation | film coated tablets |
Reference number | OW20 |
Indication | Non-metastatic hormone-sensitive prostate cancer at high risk of progression |
Company | Janssen-Cilag Ltd |
BNF chapter | Malignant disease & immunosuppression |
Submission type | One Wales |
Status | In progress |
Date of issue | 06/06/2022 |